Palvella Therapeutics PVLA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$49.3M-138% | -$41.72M-177% | -$35.07M-218% | -$26.61M-222% | -$20.73M-171% | ||
| $8.68M+388% | $6.4M+671% | $4.59M— | $2.99M— | $1.78M— | ||
| -$29.1M-76.3% | -$25.01M-131% | -$25.47M— | -$20.34M— | -$16.51M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $85.89M— | ||
| $130.77M+87.6% | -$25.62M-133% | $49.36M+1,068% | $56.23M+819% | $69.71M+739% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Palvella Therapeutics generate?
- Palvella Therapeutics (PVLA) generated -$29.1M in operating cash flow over the trailing twelve months.
- What is Palvella Therapeutics's free cash flow?
- Palvella Therapeutics's free cash flow was -$15.2M over the trailing twelve months, up 67.1% year over year.
- Where does Palvella Therapeutics's cash flow data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
